Reversing bacterial resistance with accelerated assay development

A new automated method for high-dimensional assay development is enabling researchers to rapidly identify drug candidates targeting bacterial resistance mechanisms. This advancement, made possible through a collaboration between the University of Oxford, JMP, and Synthace, focuses on the RecBCD enzyme and marks a significant step forward for drug discovery in the fight against antibiotic-resistant bacteria.

https://share.vidyard.com/watch/7wwZnPrMoDYDypH8YQ5dPn

Adam Winnifrith
University of Oxford

Markus Gershater
CEO & Co-Founder, Synthace

To read more about the research discussed in this video, please see the RSC Chemical Biology paper.

Adam Winnifrith, Steven R. Brown, Piotr Jedryszek, C. Grant, Philip E. Kay, Adam M. Thomas, Jacob D. Bradbury and Thomas Lanyon-Hogg. Development of a fluorescence-based assay for RecBCD activity using functional data analysis and design of experiments. RSC Chemical Biology: DOI: 10.1039/d4cb00291a

Success Story Infographic Template - 11

The results illustrated in this article are specific to the particular situations, business models, data input, and computing environments described herein. Each JMP customer’s experience is unique, based on business and technical variables, and all statements must be considered nontypical. Actual savings, results, and performance characteristics will vary depending on individual customer configurations and conditions. JMP does not guarantee or represent that every customer will achieve similar results. The only warranties for JMP products and services are those that are set forth in the express warranty statements in the written agreement for such products and services. Nothing herein should be construed as constituting an additional warranty. Customers have shared their successes with JMP as part of an agreed-upon contractual exchange or project success summarization following a successful implementation of JMP software.